A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)Janssen Research & Development
ClinicalTrials.gov Identifier: NCT03915379
Investigators at Janssen Research & Development have opened a Phase I clinical trial to determine the recommended dose(s) (RP2D), schedule, maximum tolerated dose, safety and tolerability, and preliminary clinical activity of JNJ-67571244 (a bispecific antibody targeting CD33 and CD3) in adult patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes who are ineligible for or have exhausted standard therapeutic options.
One center, the Sarah Cannon Research Institute in Nashville, Tennessee, is currently recruiting participants. Other centers planned for the study in the United States and Spain are not yet recruiting.
See additional details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to email@example.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.